Short Interest in Nanobiotix S.A. – Sponsored ADR (NASDAQ:NBTX) Grows By 114.6%

Nanobiotix S.A. – Sponsored ADR (NASDAQ:NBTX) was the target of a large growth in short interest in May. As of May 15th, there was short interest totaling 80,248 shares, a growth of 114.6% from the April 30th total of 37,392 shares. Based on an average daily volume of 114,555 shares, the days-to-cover ratio is presently 0.7 days. Approximately 0.2% of the shares of the company are short sold.

Analysts Set New Price Targets

NBTX has been the topic of a number of research reports. HC Wainwright reissued a “buy” rating on shares of Nanobiotix in a report on Monday, May 18th. TD Cowen reiterated a “buy” rating on shares of Nanobiotix in a research report on Thursday, March 12th. UBS Group increased their price target on shares of Nanobiotix from $3.50 to $30.00 and gave the stock a “neutral” rating in a report on Friday, May 1st. Guggenheim lifted their price objective on shares of Nanobiotix from $26.00 to $36.00 and gave the company a “buy” rating in a research note on Thursday, April 2nd. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Nanobiotix in a report on Tuesday, April 21st. Four analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, Nanobiotix currently has a consensus rating of “Moderate Buy” and an average target price of $26.67.

Nanobiotix Stock Performance

Shares of NBTX stock traded down $1.66 on Tuesday, hitting $36.34. The company had a trading volume of 54,542 shares, compared to its average volume of 86,810. Nanobiotix has a twelve month low of $4.10 and a twelve month high of $57.14. The company has a 50-day moving average price of $36.77 and a 200-day moving average price of $28.56.

Nanobiotix (NASDAQ:NBTX) last posted its earnings results on Sunday, February 15th. The company reported ($0.23) earnings per share for the quarter. The firm had revenue of $3.42 million for the quarter. On average, equities analysts expect that Nanobiotix will post 0.19 EPS for the current year.

Institutional Trading of Nanobiotix

Several institutional investors have recently modified their holdings of NBTX. Royal Bank of Canada increased its stake in shares of Nanobiotix by 2,000.0% during the fourth quarter. Royal Bank of Canada now owns 2,625 shares of the company’s stock worth $61,000 after purchasing an additional 2,500 shares in the last quarter. Optiver Holding B.V. purchased a new position in Nanobiotix in the 3rd quarter valued at about $101,000. Marshall Wace LLP acquired a new stake in Nanobiotix in the 4th quarter worth about $220,000. Finally, Millennium Management LLC purchased a new stake in Nanobiotix during the 4th quarter worth approximately $390,000. Institutional investors and hedge funds own 38.81% of the company’s stock.

About Nanobiotix

Nanobiotix is a clinical-stage biotechnology company headquartered in Paris, France, specializing in the development of novel nanopharmaceuticals to improve cancer treatment. The company’s lead product, NBTXR3, is a first-in-class radioenhancer composed of hafnium oxide nanoparticles designed to amplify the effect of radiotherapy on tumor cells while sparing surrounding healthy tissue. Nanobiotix has established clinical programs across multiple cancer indications, including soft tissue sarcoma, head and neck cancer, and hepatocellular carcinoma.

Since its inception, Nanobiotix has advanced NBTXR3 through pivotal trials and secured CE Mark approval in Europe for the treatment of soft tissue sarcoma.